The Journal Of Clinical And Aesthetic Dermatology[JOURNAL]
Sun
200 papers
The Correlation between Hidradenitis Suppurativa and Irritable Bowel Diseases: A Systematic Review.
Alhaj Z, Almubaid Z, Kleto G … +4 more , Ahmad N, Rojas V, Pinto-Cuberos J, Munoz Gonzalez A
J Clin Aesthet Dermatol · 2025 May · PMID 40538531
BACKGROUND: Hidradenitis suppurativa (HS) is an inflammatory skin condition that presents with nodules or abscesses associated with sinus tracts. Inflammatory bowel diseases (IBD) are inflammatory gastrointestinal (GI) c...
BACKGROUND: Hidradenitis suppurativa (HS) is an inflammatory skin condition that presents with nodules or abscesses associated with sinus tracts. Inflammatory bowel diseases (IBD) are inflammatory gastrointestinal (GI) conditions presenting with irregular bowel movements. Although HS and IBDs may have similarities in their clinical presentation and pathophysiology, they can differ in their cutaneous manifestations. Both conditions are potentially caused by genetic changes in the human leukocyte antigen (HLA), cause skin inflammation, and are characterized by abscesses in the GI and sinus tracts. OBJECTIVE: We sought to determine the extent of coincident IBD and HS and the associated risk factors. METHODS: The Ovid Medline database was searched for all current literature on the correlations between HS and IBD. Articles were then included and removed according to specific inclusion and exclusion criteria, and a systematic review was performed on the remaining articles. RESULTS: Thirteen papers that met the inclusion and the exclusion criteria were selected, and after data collection, a significant correlation was found between the development of HS and IBD. Most of the articles reviewed stated that the corresponding association was a causal link between the two diseases. Furthermore, there were various risk factors and comorbidities associated with HS and the development of IBD, including smoking, obesity, perianal disease, and genetic predispositions such as HLA-B27 mutations. DISCUSSION: Studies show that there is a potential correlation with HS and IBDs. Additional research should to determine the genetic correlations between HS and IBDs and the underlying pathophysiological mechanism.
Feasibility of IDEOM's Clinical Framework to Optimize Psoriatic Arthritis Care: A Cross-sectional Quality Improvement Study.
Ball GD, Hamade H, Romanelli S … +8 more , Zundell MP, Shin S, Senthilkumaran T, Lamb A, Khattri S, Perez-Chada L, Merola JF, Gottlieb AB
J Clin Aesthet Dermatol · 2025 May · PMID 40538530
Abstract loading — click title to view on PubMed.
Ferulic Acid Use for Skin Applications: A Systematic Review.
Roux J, Horton L, Babadjouni A … +2 more , Kincaid CM, Mesinkovska NA
J Clin Aesthet Dermatol · 2025 May · PMID 40538529
OBJECTIVE: Ferulic acid (FA) is gaining popularity in skincare products for its antioxidant and anti-inflammatory properties. However, its effectiveness and optimal use in humans require critical evaluation. This study a...
OBJECTIVE: Ferulic acid (FA) is gaining popularity in skincare products for its antioxidant and anti-inflammatory properties. However, its effectiveness and optimal use in humans require critical evaluation. This study aims to review the use of topical FA in skincare. METHODS: A search of PubMed and Cochrane using keywords related to skin effects and ferulic acid was conducted. Studies involving human subjects from January 1983 to June 2023 were included. RESULTS: Eighteen human studies have investigated the efficacy of FA in various cutaneous conditions, demonstrating effectiveness in enhancing one or more aspects such as skin erythema, pigmentation, hydration, elasticity, and texture. FA proved effective both alone and in combination with other active ingredients, and in subjects with and without dermatologic diagnoses. LIMITATIONS: The main limitations of this review include small sample sizes, limited diversity in study populations (Fitzpatrick skin types), a lack of robust randomized controlled trials, and varying compositions of formulations across studies which make it challenging to isolate FA's specific contributions. CONCLUSION: Existing literature supports the effectiveness of FA-containing formulations in reducing skin erythema, hyperpigmentation, and signs of aging in adults. Further studies are warranted to better understand and characterize FA's efficacy and mechanisms in treating skin conditions.
Safety Evaluation of Topical Products Containing Live Cultures and Ferment of Cutibacterium Acnes Subspecies Defendens Strain XYCM42 in Individuals Predisposed to Acne Vulgaris.
Alqam ML, Jones BC, Hitchcock TM
J Clin Aesthet Dermatol · 2025 May · PMID 40538528
BACKGROUND: For individuals with acne-prone skin, identifying a topical regimen that does not lead to progression of their inflammatory issues often poses a challenge. A topical skin probiotic regimen containing a specif...
BACKGROUND: For individuals with acne-prone skin, identifying a topical regimen that does not lead to progression of their inflammatory issues often poses a challenge. A topical skin probiotic regimen containing a specific strain of subspecies , XYCM42, has been shown to be beneficial in improving skin health and appearance in individuals with generally healthy skin, but the use of the skin probiotic has not been sufficiently assessed in individuals with acne-prone skin. OBJECTIVE: The purpose of this study was to evaluate the safety and efficacy of daily application of a topical skin biome care regimen containing a living subsp. derivative strain, XYCM42, its ferment, and adjunct topicals in individuals with acne-prone skin. METHODS: This eight-week study was conducted at five locations and included 136 total participants. At baseline, Week 1, Week 4, and Week 8, subjects completed product questionnaires and symptom severity surveys. Of the study subjects, 20 were enrolled for clinical efficacy evaluation at all timepoints. Clinical assessments included blemish lesion counts, Investigator's Global Assessment (IGA) of acne lesion severity, and clinical grading of skin cosmetic and safety parameters. RESULTS: As early as Week 1 of regimen application, clinical observations demonstrated statistically significant improvements in acne severity scores, with no subjects reporting increased or worsened acne during the study. By Week 4, subjects showed significant changes in nearly all skin cosmetic parameters assessed, including skin texture, clarity, tone, fine wrinkling, undereye dark circles, dryness, and erythema. Lesion counts were significantly reduced from baseline at all timepoints, with 100 percent of subjects experiencing fewer non-inflammatory lesions and 70 percent and 30 percent with fewer papule and pustule inflammatory lesions, respectively, by the end of the study. No adverse events were reported. CONCLUSION: This at-home use study demonstrates that use of the XYCM42-based topical skin biome care regimen is both safe and appropriate for individuals with acne-prone skin. More broadly, the outcomes of this study provide further support toward the beneficial and commensal nature of subsp. in promoting skin health.
A Review of Neoadjuvant PD-1 Inhibitors in the Setting of Cutaneous Malignancies.
Darnall AR, Baltazar D, Hamann D … +2 more , Zeitouni N, Moser J
J Clin Aesthet Dermatol · 2025 May · PMID 40538527
Considering the rapid pace of developments in the field of cancer immunotherapy, continuous updates on the topic are critical for the medical community. With incidences of cutaneous malignancies on the rise, it is more i...
Considering the rapid pace of developments in the field of cancer immunotherapy, continuous updates on the topic are critical for the medical community. With incidences of cutaneous malignancies on the rise, it is more imperative than ever to utilize and understand current and future treatment modalities. Currently, the United States (US) Food and Drug Administration (FDA) approval for various immune checkpoint inhibitors (ICIs), particularly programmed cell death protein 1 (PD-1) inhibitors, in an adjuvant setting for various cutaneous malignancies is the mainstay in treatment of a number of cutaneous malignancies. Given the transformative potential of PD-1 inhibitors within the realm of immunotherapy, an understanding of the current state of research in this area is essential for dermatologists. This is important because in the cutaneous oncological world, neoadjuvant therapy is quickly demonstrating to show significant importance skin cancer treatment. Traditional neoadjuvant therapy involves a combination of chemotherapy, radiation, and/or targeted therapy, depending on the type and stage of malignancy. The main objective in these therapies has been to reduce tumor size for improved operability, manage systemic disease, and treat operable tumors prior to surgical intervention to obtain a more favorable long-term survivability. This review aims to provide a succinct analysis of both recent and current research of PD-1 inhibitors in the neoadjuvant setting of melanoma, squamous cell carcinoma, and merkel cell carcinoma.
The Treatment of Pembrolizumab-Induced Pruritus with Topical Roflumilast Cream 0.3% Once Daily.
Lomax L
J Clin Aesthet Dermatol · 2025 May · PMID 40538526
Pembrolizumab is an immune checkpoint inhibitor that is used in the treatment of various cancers. The reported mode of action of pembrolizumab is via binding to the PD-1 receptor which leads to blocking both immune-suppr...
Pembrolizumab is an immune checkpoint inhibitor that is used in the treatment of various cancers. The reported mode of action of pembrolizumab is via binding to the PD-1 receptor which leads to blocking both immune-suppressing ligands, PD-L1 and PD-L2, from interacting with PD-1 to modulate the immune response. A common side effect of immune checkpoint inhibitors is pruritus, reported to occur in 14 to 47 percent of patients, which often reduces overall quality of life. This case report chronicles a patient suffering from significant pruritus and a lichenoid skin eruption after initiation of pembrolizumab treatment that was refractory to topical corticosteroid therapy, narrow band ultraviolet B light, and application of emollients. A topical phosphodiesterase-4 (PDE-4) inhibitor, roflumilast cream 0.3%, was subsequently initiated. Roflumilast is a selective inhibitor of PDE-4, approved by the United States Food and Drug Administration (FDA) in a 0.3% cream vehicle in 2022 for treatment of plaque psoriasis of any severity, and in a 0.3% foam vehicle in 2023 for treatment of seborrheic dermatitis of any severity. In 2024, roflumilast was FDA-approved in a 0.15% cream vehicle for treatment of mild-to-moderate atopic dermatitis in patients six years of age and older. In this adult patient, pruritus was improved within 48 hours after initiation of roflumilast cream 0.3% applied once daily and continued to be effective with use over time.
A Clinician's Guide to Dupilumab-related Ocular Surface Disease.
Assaf S, Lio P, Del Rosso JQ
J Clin Aesthet Dermatol · 2025 May · PMID 40538525
Atopic dermatitis (AD) commonly presents in both children and adults with pruritic, eczematous lesions that can have a substantial impact on quality of life. Current biologics approved for AD include dupilumab, an IL-4 r...
Atopic dermatitis (AD) commonly presents in both children and adults with pruritic, eczematous lesions that can have a substantial impact on quality of life. Current biologics approved for AD include dupilumab, an IL-4 receptor alpha inhibitor, tralokinumab, an IL-13 inhibitor, lebrikizumab, an IL-13 inhibitor, and nemolizumab, an IL-31 receptor alpha inhibitor. Dupilumab, tralokinumab, and lebrikizumab are highly effective in addressing the inflammatory response and reducing pruritus in AD patients via the IL-13 pathway, but are also associated with conjunctivitis and ocular surface disorders (OSD) in some patients, especially compared to other biologics that do not inhibit the activity of IL-4 and/or IL-13. For practitioners, it is important to be aware that OSD is a relatively common side effect but rarely causes problems severe enough to lead to cessation of treatment. This brief report provides guidance on screening and managment of OSD in patients with AD receiving anti-IL-4 and/or IL-13 treatment.
Condyloma HPV Typing: A Clinical Necessity?
Han H, Yousefian F, Smythe C … +2 more , Cockerell CJ, Nestor M
J Clin Aesthet Dermatol · 2025 May · PMID 40538524
Abstract loading — click title to view on PubMed.
Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series.
Greenberg ABW, Shahriari M, Cameron MC … +11 more , Payette M, Dasilva DR, Damiani G, Herman EI, Eminger LA, Issa NT, Rodriguez A, Del Rosso JQ, Kang Y, Cohen JM, Bunick CG
J Clin Aesthet Dermatol · 2025 May · PMID 40538523
Atopic dermatitis (AD) is a chronic inflammatory skin condition that often requires systemic treatment to achieve optimal clinical outcomes. The clinical and immunological heterogeneity of AD necessitates the use of vari...
Atopic dermatitis (AD) is a chronic inflammatory skin condition that often requires systemic treatment to achieve optimal clinical outcomes. The clinical and immunological heterogeneity of AD necessitates the use of various therapies to maximize efficacy while minimizing adverse events (AEs). Dupilumab, the first biologic agent approved by the United States Food and Drug Administration (FDA) for moderate-to-severe AD, targets interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathways. Although effective, some patients experience dupilumab-associated musculoskeletal AEs, such as arthralgia, arthritis, or enthesitis, which may lead to discontinuation of treatment. Recent studies suggest that IL-4 inhibition disrupts T-cell populations, promoting a skewed T-helper 17 (Th17)-dominant immune response that may contribute to arthralgia. Switching to alternative therapies, such as tralokinumab-an IL-13-specific inhibitor-has shown promise in alleviating these AEs while maintaining control of AD signs and symptoms. Case reports indicate that patients with dupilumab-associated arthralgia have improved after switching to tralokinumab, suggesting the potential of tralokinumab as a safer alternative for these individuals. We present a series of 15 AD patients treated with tralokinumab following discontinuation of dupilumab due to arthralgia. All 15 patients achieved clear or nearly clear skin and demonstrated reductions in AD signs and symptoms as measured by Investigator's Global Assessment (IGA), body surface area of involvement (BSA), and/or patient reported measures of pruritus. Importantly, all patients experienced resolution of arthralgia without recurrence while on tralokinumab. These findings support the use of tralokinumab as an effective and safe alternative therapy for patients with dupilumab-induced arthralgia.
Red-Light Photodynamic Therapy with 10% Aminolevulinic Acid (ALA) Following Microneedling in the Treatment of Facial Actinic Keratosis: Cosmetic and Clinical Outcomes.
Goldenberg G, Schwartz Z, Yousefian F
J Clin Aesthet Dermatol · 2025 Apr · PMID 40256344
OBJECTIVE: We evaluated the cosmetic outcome and clearance of actinic keratoses (AKs) using photodynamic therapy (PDT) with microneedling-assisted delivery of 10% aminolevulinic acid (ALA) gel (Ameluz®, Biofrontera, Wobu...
OBJECTIVE: We evaluated the cosmetic outcome and clearance of actinic keratoses (AKs) using photodynamic therapy (PDT) with microneedling-assisted delivery of 10% aminolevulinic acid (ALA) gel (Ameluz®, Biofrontera, Woburn, MA) with 30-minute incubation followed by 10-minute illumination with a red light (BF-RhodoLED®, 635nm, 37 J/cm). METHODS: Five subjects were treated with red light PDT using microneedling-assisted delivery of 10% ALA gel. ALA gel was applied on the face and incubated for 30 minutes without occlusion, followed by illumination with a red light for 10 minutes (635nm, 37 J/cm). Follow-up (FU) visits were made at Weeks 1, 2, 4, and 8. The primary endpoints were changes in subject- and investigator-graded Global Aesthetic Improvement Scale (GAIS) scores and assessment of quality in wrinkle, color evenness, texture, spot, and pore analyses with Canfield Visia-CR imaging system. Secondary endpoints were: 1) AK clearance as quantified by the count of AKs at eight-week FU versus baseline and 2) safety as measured by subject-reported pain (10-point VAS scale) during red-light illumination and adverse events. RESULTS: Investigator- and subject-graded GAIS scores showed a sharp increase to "much improved" at two weeks and increased to "very much improved" at eight weeks. There was an average 24.93-percent improvement in texture and an average 10.30-percent improvement in skin tone (color) evenness. AK lesion clearance ranged from 70 to 100 percent, with the mean at 89.2±14.9 percent. Three subjects achieved 100-percent clearance. The mean pain score during red-light illumination was 3.2±1.6. All subjects completed the study. LIMITATIONS: The study included a small number of subjects (N=5). CONCLUSION: Our results indicate that red light PDT using microneedling-assisted delivery of 10% ALA gel and a short 30-minute incubation is a safe and tolerable procedure producing good cosmetic outcomes in several skin quality parameters, such as texture and skin tone evenness, as well as an AK lesion clearance rate of 89.2 percent at Week 8, relatively low pain scores, and a reduced PDT treatment time.
Impact of the COVID-19 Pandemic on the Diagnosis and Treatment of Cutaneous Melanoma in a Public Health Service in Brazil.
da Silva Carvalho AC, de Magalhães Ledsham Lopes C, Lobo AR … +3 more , de Assis IA, de Medeiros HL, Drummond-Lage AP
J Clin Aesthet Dermatol · 2025 Apr · PMID 40256343
OBJECTIVE: The authors sought to evaluate the impact of the COVID-19 pandemic on the incidence, tumor thickness, and time between diagnosis and first treatment of cutaneous melanoma patients. METHODS: A retrospective obs...
OBJECTIVE: The authors sought to evaluate the impact of the COVID-19 pandemic on the incidence, tumor thickness, and time between diagnosis and first treatment of cutaneous melanoma patients. METHODS: A retrospective observational study was conducted based on the analysis of electronic medical records of patients treated at a reference service in Cutaneous Oncology within the scope of the Unified Health System in Belo Horizonte, Brazil. The population was evaluated according to the date of diagnosis and was classified into three periods: 1) pre-pandemic period (January 2019 to March 2020), 2) pandemic period 1 (April 2020 to June 2021), and 3) pandemic period 2 (July 2021 to September 2022). Sociodemographic characteristics of the study population, tumor characteristics, and the time interval between diagnosis and first treatment were evaluated. RESULTS: Seventy-six patients were evaluated, 25 (32.89%) diagnosed in the pre-pandemic period, 22 (28.94%) in pandemic period 1, and 29 (38.15%) in pandemic period 2. No significant differences were observed between the sociodemographic characteristics of the population, tumor thickness, and the presence of ulceration in the three periods analyzed. There was also no delay between diagnosis and the first treatment during the pandemic. LIMITATIONS: The size of the population, and the use of retrospective data extracted from medical records, without a systematized record of information. CONCLUSION: The COVID-19 pandemic did not impact the incidence, thickness of melanomas, or the time between diagnosis and first treatment. This study demonstrated the importance of adapting the routine of health services and adapting the flow of oncology care in times of health crisis.
What Does it Mean to Be Beautiful? Exploring the Limits of AI-Driven Beauty Assessment.
Ashley E, Walker L, Chadha P
J Clin Aesthet Dermatol · 2025 Apr · PMID 40256342
This paper examines the multifaceted nature of beauty, encompassing evolutionary, biological, neurological, cultural, and individual factors. It explores the limitations of objective assessments, such as artificial intel...
This paper examines the multifaceted nature of beauty, encompassing evolutionary, biological, neurological, cultural, and individual factors. It explores the limitations of objective assessments, such as artificial intelligence (AI) algorithms like the Facial Aesthetic Index and Facial Youthfulness Index, which often fail to capture the diversity of individual preferences and cultural standards. While AI tools can provide valuable insights into facial features, their use in aesthetic medicine should be approached with caution, recognizing the importance of subjective perceptions. We emphasize the need for a collaborative approach that integrates AI insights with clinical expertise and patient involvement to achieve personalized and satisfying outcomes in aesthetic medicine. Ultimately, beauty is a complex and subjective experience that cannot be fully defined or assessed objectively, and successful aesthetic interventions require a holistic approach that values both objective data and individual perspectives.
A Non-randomized, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of 10% Aminolevulinic Acid Gel in the Expanded Field-directed Treatment of Actinic Keratosis on the Face and Scalp with Red Light Photodynamic Therapy.
Cohen JL, Tu JH, Couvillion MP … +9 more , Jazayeri SS, Zeitouni NC, Ibrahim SF, Lain EL, Hanke CW, Zogel C, Schmitz B, Zeuner MT, Schlesinger T
J Clin Aesthet Dermatol · 2025 Apr · PMID 40256341
OBJECTIVE: Dermatologists regularly encounter patients having expanded fields with numerous actinic keratosis (AK) lesions on the face and scalp. Field-directed red light photodynamic therapy (PDT) is a well-established...
OBJECTIVE: Dermatologists regularly encounter patients having expanded fields with numerous actinic keratosis (AK) lesions on the face and scalp. Field-directed red light photodynamic therapy (PDT) is a well-established treatment, yet published data on the safety of PDT on large areas is scarce. We aimed to evaluate the safety and tolerability of red light PDT in treating expanded AK fields on the face and scalp. METHODS: This was a non-randomized, open-label, multicenter study. After lesion preparation, 6g of 10% aminolevulinic acid (ALA) gel were applied to the treatment field (60 cm) and incubated for three hours under a light-blocking, occlusive dressing before 10-minute illumination with a red light lamp (~635nm, 37 J/cm). Safety and tolerability were assessed throughout the study. RESULTS: All participants (n=100) had adverse reactions. No previously unknown effects, serious adverse events, or deaths were reported. The most frequent application site reactions were pain/burning (96.0%), exfoliation (87.0%), and erythema (86.0%). Most treatment-emergent adverse events were of mild to moderate severity and lasted slightly longer compared to those experienced after treatment of smaller areas. The mean maximum pain during PDT was 7.4±2.1 on an 11-point numeric rating scale. A transient increase in blood pressure on the day that PDT was performed was not clinically significant. LIMITATIONS: Although the allowed use of pain-reducing measures might have influenced evaluation of pain, it reflects how the procedure is managed in current practice. CONCKLUSION: PDT with 10% ALA gel and red light illumination on an expanded treatment field was generally well tolerated.
Exosomes: A Comprehensive Review for the Practicing Dermatologist.
Mahmoud RH, Peterson E, Badiavas EV … +2 more , Kaminer M, Eber AE
J Clin Aesthet Dermatol · 2025 Apr · PMID 40256340
This clinical review examines what is known about exosomes and their applicability to aesthetic dermatology. Exosomes are extracellular vesicles with crucial roles in intercellular communication. Their biogenesis is comp...
This clinical review examines what is known about exosomes and their applicability to aesthetic dermatology. Exosomes are extracellular vesicles with crucial roles in intercellular communication. Their biogenesis is complex and not completely understood, but they are generally formed intracellularly in the endosomal compartment of a cell or through direct plasma membrane release. Several mechanisms of exosome uptake have been described and are dependent on the molecular characteristics of the recipient cell and exosome membrane. Furthermore, there are a multitude of exosome isolation and characterization techniques, each with their own potential advantages and disadvantages. Exosomes have demonstrated promise in preclinical models across various domains of aesthetic dermatology, including as anti-aging and anti-inflammatory therapies and as therapeutics for wound healing, scar reduction, and hair regeneration. However, clinical studies are lacking, and there are substantial safety concerns, such as the potential risk of infections, unwanted inflammatory response, and promotion of malignancy. Further research is needed to develop more precise analytical techniques to better understand the composition of exosomes, their safety profiles, and their potential applications to patient care.
Positioning and Protecting the Patient is Essential for Safe, Quality, Efficient Surgery.
Ceilley RI, Sureshbabu S
J Clin Aesthet Dermatol · 2025 Apr · PMID 40256339
Optimizing ergonomics and patient positioning is essential for enhancing patient safety and improving outcomes in dermatologic surgery. Proper patient positioning can prevent provider strain, improve surgical accuracy, a...
Optimizing ergonomics and patient positioning is essential for enhancing patient safety and improving outcomes in dermatologic surgery. Proper patient positioning can prevent provider strain, improve surgical accuracy, and increase overall efficiency. Key strategies include maintaining a neutral body plane, providing neck and knee support, and shielding the eyes to reduce patient stress. Adjustments in limb positioning can enhance skin laxity and tension management, facilitating better wound closure and healing. Equally important is the surgeon's ergonomics, with proper posture, adjustable seating, and strategic breaks to reduce fatigue and improve performance. Attention to these factors supports both patient comfort and long-term sustainability of high-quality care.
Efficacy and Safety of Fixed-dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Black Participants with Moderate to Severe Acne.
Callender VD, Alexis AF, Bhatia N … +4 more , Harper JC, Baldwin H, Guenin E, Kircik LH
J Clin Aesthet Dermatol · 2025 Apr · PMID 40256338
OBJECTIVE: Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel-the only approved fixed-dose, triple-combination acne treatment-demonstrated superior efficacy to vehicle and component dyads, with fa...
OBJECTIVE: Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel-the only approved fixed-dose, triple-combination acne treatment-demonstrated superior efficacy to vehicle and component dyads, with favorable safety/tolerability in Phase 2 and Phase 3 studies. In order to examine efficacy and safety of CAB in patients with darker skin phototypes, a post hoc analysis of clinical trial data of participants who self-identified as "Black or African American" was conducted. METHODS: Data were pooled from two Phase 2 and two Phase 3, double-blind, 12-week studies (NCT03170388, NCT04892706, NCT04214639, NCT04214652). Eligible participants aged ≥9 years (≥12 years in NCT04892706) were randomized to once-daily CAB or vehicle. Endpoints included ≥2-grade reduction from baseline in Evaluator's Global Severity Score and clear/almost clear skin (treatment success) and inflammatory/noninflammatory lesion counts. Treatment-emergent adverse events (TEAEs) and cutaneous safety/tolerability were also assessed. RESULTS: Of 1,115 participants randomized to CAB or vehicle, 156 (14%) were Black. At Week 12, 32.0 percent of CAB-treated participants achieved treatment success versus 18.3 percent with vehicle (=0.07). Inflammatory and noninflammatory lesion reductions were significantly greater with CAB versus vehicle (68.8% vs. 51.4% and 57.8% vs. 45.5%, respectively; <0.05, both). TEAE severity was mild to moderate, and hyperpigmentation mean scores remained at/below baseline value (0.7; 1=mild). LIMITATIONS: Studies were not powered to detect significant differences between CAB and vehicle for Black participants; therefore, values are for informative purposes only. CONCLUSION: CAB gel was efficacious and well tolerated in Black participants with acne.
Evaluation of a Dermocosmetic Serum Containing a Multi-acid Complex and Niacinamide in Japanese Women with Mild Acne.
Igarashi A, Abe M, Gunji Y … +5 more , Nemoto O, Kawamura K, Yokozeki M, Saito A, Ookawara A
J Clin Aesthet Dermatol · 2025 Apr · PMID 40256337
BACKGROUND: Acne is a common inflammatory dermatosis in all parts of the world, including Japan. While effective prescription treatments are available, patients often prefer to try to manage their acne, particularly when...
BACKGROUND: Acne is a common inflammatory dermatosis in all parts of the world, including Japan. While effective prescription treatments are available, patients often prefer to try to manage their acne, particularly when it is mild, using over-the-counter (OTC) approaches. OBJECTIVE: This open-label study evaluated the efficacy and safety of an OTC serum containing a multi-acid complex and niacinamide (niacinamide 2%, lactic acid 1%, hydroxyethylpiperazine ethane sulfuric acid [HEPES] 0.5%, phytic acid 0.2%, and salicylic acid 0.2%) used twice daily for eight weeks in Japanese women aged 16 to 34 years with acne. METHODS: An eight-week, split-face, open-label study of multi-acid complex and niacinamide containing dermocosmetic used twice daily in Japanese women aged 16 to 34 years was conducted. Participants had mild-to-moderate inflammatory acne (up to 20 inflammatory lesions on half the face) and assessments included number and severity of acne lesions as well as standard safety assessments. RESULTS: A total of 50 women enrolled, with 46 eligible for evaluation at Week 8. Significant improvements in acne severity, the number of inflammatory lesions, and skin texture as indicated by pore size were observed (<0.05 for all). In addition, patients' quality of life significantly improved from baseline to Week 8 (<0.01). The serum was well tolerated. Four cases of skin discomfort were reported; all were mild in severity and resolved spontaneously. CONCLUSION: This multi-acid/niacinamide OTC serum effectively improved acne in Japanese women.
Gender Bias in Topical Minoxidil Labeling and Pricing.
Salas J, Cices A
J Clin Aesthet Dermatol · 2025 Apr · PMID 40256336
Abstract loading — click title to view on PubMed.
Treatment of Recalcitrant Hailey-Hailey Disease with Dupilumab: A Case Report.
Sulich-Moore C, Altman D, Gildenberg S
J Clin Aesthet Dermatol · 2025 Apr · PMID 40256335
Hailey-Hailey disease is a rare autosomal dominant genodermatosis clinically characterized by recurrent flaccid bullae, erosive plaques, and linear epidermal tears primarily affecting intertriginous areas. This case repo...
Hailey-Hailey disease is a rare autosomal dominant genodermatosis clinically characterized by recurrent flaccid bullae, erosive plaques, and linear epidermal tears primarily affecting intertriginous areas. This case report describes a 34-year-old White female with a 15-year history of severe, treatment-refractory Hailey-Hailey disease affecting multiple intertriginous areas. After failing numerous topical and systemic therapies, the patient initiated dupilumab therapy with a 600mg loading dose followed by 300mg administered every two weeks as maintenance. Within four months, the patient demonstrated approximately 80 percent clinical improvement with significant reduction in pain and pruritus. The authors speculate dupilumab's efficacy may extend beyond calcium homeostasis regulation, potentially addressing an unrecognized autoimmune component of Hailey-Hailey disease wherein desmosomal disruption may expose normally protected epitopes to immune surveillance. The rapid clinical response to dupilumab in this previously treatment-refractory case warrants further investigation into the immunopathogenesis of Hailey-Hailey disease and supports dupilumab as a promising therapeutic option for this debilitating condition.
Race Reporting in Dermabrasion Clinical Trials: A Systematic Review.
Kamboj S, Blalock TW
J Clin Aesthet Dermatol · 2025 Apr · PMID 40256334
OBJECTIVE: The authors sought to determine the frequency and methods of race reporting in dermabrasion clinical trials. METHODS: A PubMed search for terms: "dermabrasion," "derm-abrasion," and "derm abrasion" was conduct...
OBJECTIVE: The authors sought to determine the frequency and methods of race reporting in dermabrasion clinical trials. METHODS: A PubMed search for terms: "dermabrasion," "derm-abrasion," and "derm abrasion" was conducted, yielding 1,786 papers. The "Clinical Trial" and "Randomized Control Trial" filters were applied. Non-English manuscripts were excluded. Remaining manuscripts were manually screened. Forty-one papers met final inclusion criteria. RESULTS: Forty-six percent (n=19) of studies included mention of race, skin color, or Fitzpatrick skin type (FST). Four studies reported FST of 78 dermabrasion participants. Of these, 19 percent had FST I, 27 percent had FST II, 32 percent had FST III, 17 percent had FST IV, and 1 percent had FST V. Three patients (4%) were lost to follow-up and did not have FSTs reported. Twenty-two percent (n=9) of the studies including 513 patients reported race or skin color. The races of 107 (21%) could be definitively extracted. Of these 107 patients, 94 percent were White, five percent were Black, and one percent were Asian. LIMITATIONS: Our search was limited to PubMed-indexed articles which were categorized as 1) clinical trials or 2) randomized control trials. Articles that were incorrectly indexed in accordance with the search tool may have been inadvertently excluded. CONCLUSION: Our analysis suggests that the collection and reporting of racial demographic information has been rare in dermabrasion clinical trials. The absence of this demographic information limits the generalizability of the results. Given the health disparities that arise due to racism, investigators should collect and report participant races to improve risk stratification and transparency.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe